Literature DB >> 22291789

The role of the immunoinflammatory response after cardiac arrest.

Nora Sandu1, Amr Abdulazim, Toma Spiriev, Belachew Arasho, Bernhard Schaller.   

Abstract

Entities:  

Year:  2011        PMID: 22291789      PMCID: PMC3258775          DOI: 10.5114/aoms.2011.24122

Source DB:  PubMed          Journal:  Arch Med Sci        ISSN: 1734-1922            Impact factor:   3.318


× No keyword cloud information.
Cardiac arrest is a good (experimental) model for research in ischaemic tolerance [1], so it has been used often during the last 20 years in animal models. The (global) ischaemic event induced by cardiac arrest is followed by a phase of ischaemic preconditioning if the initial phase was of shorter or even stroke/complete ischaemia if the initial phase was of longer duration [2]. During the last years, there has been great effort in different research groups all over the world to find out the underlying pathophysiological mechanisms involved after these events or at least to find out some risk factors either in the brain or in the whole body [3, 4]. In the present issue of Archives of Medical Science, Anna Samborska-Sablik et al. present an interesting manuscript that deals with the role of the immunoinflammatory response after cardiac arrest in humans [5]. It is one of the very few studies in humans after cardiac arrest and is therefore of special interest [6]. The authors could find a significant correlation of the post-cardiac-arrest immunoinflammatory response (hs-CRP and IL-6) with the patients’ clinical state and also with the prediction of survival [5]. Such data are in line with previous research in the brain [7, 8] and open the door to so-called “immunomodulatory therapy”. In the brain such research is advanced, but we need a better understanding of the brain and immune system after such ischaemic events [9]. For the whole body, nearly no data exist so far. However, Anna Samborska-Sablik et al. have now provided a better insight into the clinical relevance of such research [5]: They show the relevance of this immunoinflammatory response for Glasgow Coma Scale (GCS) and Acute Physiology and Chronic Health Evaluation II (APACHE II) score: two of the major scores used in clinical daily practice. Therefore the immunoinflammatory response after ischaemic events is not only an experimental phenomenon (as many others), but also of great clinical importance [10, 11]. What are now the therapeutic implications of these findings? In experimental studies, preventive antibiotic treatment dramatically improved survival and outcome after ischaemic events, and even reduced the organ’s infarct size area [9, 12]. Apart from these experimental studies there are several clinical trials with promising results in this direction [12]. Smaller events of shorter duration can be protective – for example in the postoperative period – for further ischaemic events [7]. In this context, the oxygen-conserving reflex has gained more interest [13, 14] and can explain – at least partly – why the brain is only damaged after a very long duration of cardiac arrest. Nevertheless, the article of Samborska-Sablik et al. [5] goes deep into the pathophysiology of different organs. Further clinical research on this topic will open widely the doors to interesting therapeutic modalities and will help to resolve one of the great problems in internal medicine. Let’s go on this way!
  11 in total

Review 1.  Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage.

Authors:  Kaisorn L Chaichana; Gustavo Pradilla; Judy Huang; Rafael J Tamargo
Journal:  World Neurosurg       Date:  2009-08-06       Impact factor: 2.104

Review 2.  Influence of age on stroke and preconditioning-induced ischemic tolerance in the brain.

Authors:  B J Schaller
Journal:  Exp Neurol       Date:  2006-04-24       Impact factor: 5.330

3.  Immune responses after acute ischemic stroke or myocardial infarction.

Authors:  Karl Georg Haeusler; Wolf U H Schmidt; Fabian Foehring; Christian Meisel; Christoph Guenther; Peter Brunecker; Claudia Kunze; Thomas Helms; Ulrich Dirnagl; Hans-Dieter Volk; Arno Villringer
Journal:  Int J Cardiol       Date:  2010-11-13       Impact factor: 4.164

4.  Trigemino-cardiac reflex and antecedent transient ischemic attacks.

Authors:  Christoph Nöthen; Nora Sandu; Hemanshu Prabhakar; Andreas Filis; Belachew D Arasho; Michael Buchfelder; Bernhard J Schaller
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-04

Review 5.  Stroke-induced immunodepression: experimental evidence and clinical relevance.

Authors:  Ulrich Dirnagl; Juliane Klehmet; Johann S Braun; Hendrik Harms; Christian Meisel; Tjalf Ziemssen; Konstantin Prass; Andreas Meisel
Journal:  Stroke       Date:  2007-02       Impact factor: 7.914

6.  Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance.

Authors:  Bernhard Schaller
Journal:  Neurosci Lett       Date:  2005-01-08       Impact factor: 3.046

7.  [Trigeminocardiac reflex in pituitary surgery. A prospective pilot study].

Authors:  A Filis; B Schaller; M Buchfelder
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

Review 8.  Ischemic tolerance in stroke treatment.

Authors:  Nora Sandu; Jan Cornelius; Andreas Filis; Belachew Arasho; Miguel Perez-Pinzon; Bernhard Schaller
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-10

9.  The role of the immuno-inflammatory response in patients after cardiac arrest.

Authors:  Anna Samborska-Sablik; Zbigniew Sablik; Wojciech Gaszynski
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

10.  Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial.

Authors:  Hendrik Harms; Konstantin Prass; Christian Meisel; Juliane Klehmet; Witold Rogge; Christoph Drenckhahn; Jos Göhler; Stefan Bereswill; Ulf Göbel; Klaus Dieter Wernecke; Tilo Wolf; Guy Arnold; Elke Halle; Hans-Dieter Volk; Ulrich Dirnagl; Andreas Meisel
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.